Redhill Biopharma Long Term Debt

Redhill Biopharma posts a long-term debt of $900K as of December 2025. That compares with $3K in the prior-year period — up 29900.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Redhill Biopharma's long-term debt was $3K. The latest reading is $900K — a 29900.0% year-over-year increase (period ending December 2025). Use the history and growth charts on this page for a longer lookback.

Long-Term Debt is one piece of Redhill Biopharma's financial statement story. At $900K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for RDHL's long-term debt usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Redhill Biopharma's other metric pages and overview cover the third.

Judging Redhill Biopharma against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in long-term debt easier to interpret. Start with $900K here, then scan peer and history charts to see if the gap is persistent.